FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma.
Anticancer Res
; 43(12): 5699-5704, 2023 Dec.
Article
em En
| MEDLINE
| ID: mdl-38030182
ABSTRACT
BACKGROUND/AIM:
Urachal carcinoma is a rare cancer, with limited evidence regarding systemic chemotherapy for metastatic urachal carcinoma. This study aimed to evaluate the efficacy and safety of a combination therapy of 5-fluorouracil and irinotecan (FOLFIRI) in patients with metastatic urachal carcinoma. PATIENTS ANDMETHODS:
Patients with metastatic urachal carcinoma treated with FOLFIRI between March 2008 and April 2023 at the Department of Medical Oncology, Tohoku University Hospital, were retrospectively analyzed using medical records.RESULTS:
Six patients with urachal carcinoma received FOLFIRI. The histological type was adenocarcinoma in all patients. The metastatic or recurrent sites were the peritoneum, lungs, lymph nodes, and local relapse sites. Three patients received FOLFIRI as first-line chemotherapy, and the other three received FOLFIRI as second-line chemotherapy. Two patients had only non-measurable lesions as the targets of tumor response. The best response was the stable disease or non-complete response/non-progressive disease in four patients, with a disease control rate of 67%. The median progression-free survival was 7.5 months. In two patients with ascites only as the site of metastasis, the amount of ascites and serum tumor marker levels decreased after FOLFIRI was initiated. Grade 3/4 toxicities included grade 3 neutropenia in one patient and grade 3 diarrhea in one patient.CONCLUSION:
FOLFIRI has modest efficacy and good tolerability for the treatment of metastatic urachal carcinoma.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Contexto em Saúde:
3_ND
Problema de saúde:
3_diarrhea
Assunto principal:
Camptotecina
/
Neoplasias Colorretais
Limite:
Humans
Idioma:
En
Revista:
Anticancer Res
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Japão